AnaCipher gets ANVISA Brazil approval for clinical and bioanalytical facilities

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

INDOCO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.3%Reaction day

₹219.20

prior close

₹219.20

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 170sector+0.6%-2.8% vs sector

On the reaction day the stock moved 2.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.0

10m

-0.7

15m

-0.4

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.3pendingpending+0.6-2.8

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Indoco Remedies said its Hyderabad-based clinical research organisation, AnaCipher, received approval from Brazil's health regulator ANVISA after an inspection from March 30 to April 7, 2026. It can now conduct bioavailability and bioequivalence studies for Brazilian submissions and provide related bioanalytical support.

Likely market impact

Approval boosts AnaCipher's global credentials and Brazil market access, though no revenue or order value was disclosed.